You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm used the proceeds to repay outstanding borrowings of $25.9 million under its existing loan with Innovatus Life Sciences Lending Fund.
For the three months ended Dec. 31, the Boulder, Colorado-based firm reported revenues of $27.0 million compared to $8.3 million in 2019.
At ACLA's annual meeting, a panel discussed how machine learning, artificial intelligence, telehealth, and at-home testing have gained traction throughout the laboratory industry.
Labs like Biodesix, ARUP, Quest, and Labcorp engaged different strategies to prevent loss of patient samples during recent extreme weather.
News items for the in vitro diagnostics industry for the week of Feb. 15, 2021.
The firms are focusing an initial program on the development of a companion diagnostic test for HiberCell’s immunotherapy, Imprime PGG.
Biodesix, which raised about $63 million in a recent initial public offering, said it ended 2020 with roughly $62 million in cash and cash equivalents.
For the three months ended Sept. 30, the Boulder, Colorado-based firm generated a revenue of $9.2 million, compared to $3.9 million year over year.
William Blair, Canaccord Genuity, and BTIG on Monday initiated coverage of newly public Biodesix, with ratings ranging from Buy to Outperform.
Shares of the Boulder, Colorado-based firm will begin trading on the Nasdaq today under ticker symbol "BDSX" at $18 per share.